Peptide Research Literature Index
A structured, dated index of the research-peptide landscape

Can a company be convicted for what it bought? A Kentucky firm pleaded guilty on three elements, and not one of them is about anything the company said

Reference page · published 2026-10-29

Disclosure: this index is operated by Artemis Labs, which sells research compounds to laboratories. Artemis Labs buys vials it did not manufacture and ships them to buyers who pay for them. The case on this page is about a company that was convicted for doing those two things with the wrong goods in the middle, so our interest in it is direct and it goes at the top of this page, not buried at the bottom. Nothing here is legal advice. If you run a business that receives anything regulated as a drug, the only correct use of this page is to take it to a lawyer. Nothing on this page tells anybody how to use any compound. Every quotation below is verbatim from a federal court filing, the United States Code, the Code of Federal Regulations, or a United States Attorney's public announcement — each document fetched and read for this page on October 29, 2026, and each listed under Sources. Three documents in this case cannot be quoted at all, including the one that contains the government's own list of the elements. A section near the end explains why, and that limitation shaped what this page can say.

Short answer: yes, and the list of things the government has to prove is shorter than most people expect. For the offense this company pleaded guilty to, the government must show that the company received a drug in interstate commerce, that the drug was misbranded, and that it was delivered for pay or otherwise. That is the whole prohibited act as Congress wrote it. There is no element about knowing the goods were misbranded, no element about intending anything, and no element about a single word the company wrote, said, or published. The first and third parts describe ordinary commerce. Everything turns on the middle one.

What happened

On June 9, 2025, a business in Laurel County, Kentucky called Facial Expressions appeared in the United States District Court for the Eastern District of Kentucky and pleaded guilty to one count. The United States Attorney's office announced it eleven days later:

A Laurel County, Kentucky company, Facial Expressions, pleaded guilty to the receipt of misbranded drugs in interstate commerce.

The business was a clinic that bought drugs derived from botulinum toxins and used them on paying customers to smooth skin wrinkles. According to the announcement, it bought them abroad:

between August 2019 and August 2023, Facial Expressions purchased botulinum toxin type A drugs that were manufactured, packaged, and labeled for sale in Korea and/or Turkey, and thus were not authorized for use inside the United States by the FDA

Two things about that sentence are worth slowing down for, because they are the whole reason this record is on this site.

First, the problem is not that the drugs were fake. Nobody alleged that. The announcement says they were manufactured, packaged, and labeled for sale in Korea and/or Turkey — real products, made for a real market, just not this one. Second, the defendant is a company. Not an executive, not an owner in her personal capacity. The caption reads United States of America v. Facial Expressions. Most criminal records in this index punish a human being for something that human being wrote. This one punishes a business for what it bought.

The prohibited act, in one sentence

The federal food and drug law lists the things it forbids. The one charged here is paragraph (c), and it is short enough to read in a breath:

The receipt in interstate commerce of any food, drug, device, tobacco product, or cosmetic that is adulterated or misbranded, and the delivery or proffered delivery thereof for pay or otherwise.

Read it looking for a state of mind. There is none. No knowingly. No willfully. No with intent to. The sentence describes two physical events — a receipt and a delivery — with a condition on the goods in between.

Break it into its parts and you have the structure of the offense:

A business that buys inventory and ships it to customers performs the first and third of those every working day. That is not a loophole or an edge case; it is a description of retail and wholesale distribution. The entire question is whether the thing in the middle was a misbranded drug.

What it costs, and the trap in the second paragraph

The penalty provision has two tiers. The first is the misdemeanor:

Any person who violates a provision of section 331 of this title shall be imprisoned for not more than one year or fined not more than $1,000, or both.

That is the tier this company pleaded to. The second tier is the felony, and it has two separate doors into it:

commits such a violation with the intent to defraud or mislead, such person shall be imprisoned for not more than three years or fined not more than $10,000, or both

Intent to defraud is one door. The other, in the same sentence, is having a prior conviction under this Act that has become final. So a first misdemeanor conviction — the kind that costs a modest fine and no prison — quietly changes the exposure on everything that comes after it. We cover that mechanism separately in what turns a misbranding charge into a felony.

The dollar figures in the statute are not what a defendant actually pays. Federal fine levels are set elsewhere, and the public announcement of the related individual case gives a sense of the real range: it said the owner, in her own separate matter, faces up to four years in prison and a maximum fine of $250,000. That is a different case against a different defendant, and we note it only so the $1,000 in the statute is not mistaken for the ceiling.

The two ways the goods were misbranded, and both are about marks on a label

The word misbranded sounds like it should mean a lie. In this Act it does not have to. It is a defined status, and a drug can fall into it without anyone saying anything false.

Two definitions were in play here. The first requires directions:

Unless its labeling bears (1) adequate directions for use

A drug whose labeling does not carry adequate directions for use is misbranded. The regulation defines what adequate means, and the standard is set by who has to follow the directions:

Adequate directions for use means directions under which the layman can use a drug safely and for the purposes for which it is intended.

A layman. Not a pharmacist, not a physician — an ordinary person with no training. Hold that thought, because it is the hinge of the whole argument.

The second definition is about a symbol:

A drug that is subject to paragraph (1) shall be deemed to be misbranded if at any time prior to dispensing the label of the drug fails to bear, at a minimum, the symbol “Rx only”.

A prescription drug whose label does not say Rx only is misbranded. That is it. No claim, no advertisement, no statement to a customer. A missing mark on a label.

The same provision runs the other way, and almost nobody mentions it

The very next subparagraph is the mirror image, and it deserves to be read by anybody who labels anything:

A drug to which paragraph (1) does not apply shall be deemed to be misbranded if at any time prior to dispensing the label of the drug bears the symbol described in subparagraph (A).

In plain language: if a drug is a prescription drug, leaving Rx only off makes it misbranded. If a drug is not a prescription drug, putting Rx only on makes it misbranded. The symbol is not decoration and it is not a cautious extra. It is a status marker, and using it wrongly in either direction is the defined offense.

This cuts against a habit that is common in our own market, where sellers sometimes add official-looking marks to a label because the marks look serious. Under this provision, a mark that claims a status the article does not have is not caution. It is the violation.

The loop that makes the result automatic, and both sides agreed to it out loud

Here is the part of this record that is genuinely unusual, and it exists only because of something that went slightly wrong in the paperwork.

When a defendant pleads guilty, the court has to satisfy itself there is a factual basis for the plea. Normally the plea agreement spells out the theory. Here it did not, so the magistrate judge had to establish it on the record. His written recommendation says so:

The Court questioned Defendant in detail concerning the factual basis, in particular ensuring that, although not specified in the plea agreement, the products at issue were misbranded as alleged in paragraph 24 of the information, meaning they lacked adequate directions for use (without a statutory exemption) and did not bear the symbol “Rx.”

And then, in the same paragraph, the court recorded a formula that the prosecution and the defense both signed off on:

both counsel agreed that “A drug is misbranded if it is a prescription drug that is an unapproved new drug, because a prescription drug cannot bear the adequate directions for use required by statute [18 U.S.C. § 352(f)(1)] and the lack of an approved NDA means that there is no FDA exemption from the adequate directions for use requirement.

Walk that in slow steps, because it is a closed circle:

  1. A prescription drug, by definition, is one that cannot be used safely without a practitioner supervising. So it cannot carry directions a layman could follow safely. The adequate-directions requirement is therefore impossible for it to meet.
  2. There is an exemption from that requirement — otherwise every prescription drug in the country would be misbranded.
  3. But the exemption is conditioned on having an approved application.
  4. So if the drug is a prescription drug and has no approved application, the requirement cannot be met and the exemption is not available. Misbranded, with nothing left to argue.

Notice what is absent from every step. No claim. No advertisement. No statement to a customer. No test result. No intent. Once the article is characterized as an unapproved prescription drug, the misbranding follows from the characterization itself.

The court cited one case for the proposition, and it is the only judicial authority named anywhere in the set of filings we read: United States v. An Article of Drug . . . “Mykocert,” 345 F. Supp. 571, 573 (N.D. Ill. 1972).

The exemption is about who is holding it, not only what the label says

The formula above leans on the exemption without quoting it. We fetched it, and it contains something the formula does not make obvious. The regulation opens like this:

A drug subject to the requirements of section 503(b)(1) of the act shall be exempt from section 502(f)(1) if all the following conditions are met

All the following conditions. The first one is not about the label at all. It is about whose hands the drug is in:

In the possession of a person (or his agents or employees) regularly and lawfully engaged in the manufacture, transportation, storage, or wholesale distribution of prescription drugs

— or a pharmacy, or a public health agency, or:

In the possession of a practitioner licensed by law to administer or prescribe such drugs

And a later condition closes the other end:

the labeling bearing such information is the labeling authorized by the approved new drug application

So the exemption that saves every lawfully distributed prescription drug in America from being misbranded has two kinds of condition bolted together: a condition about the holder and a condition about the approved labeling. A party outside that list of holders does not get the exemption even with a perfect label. A party inside the list does not get it for an article with no approved application. This is the step the agreed formula compresses into one clause, and it is worth seeing in full, because it explains why the status of the buyer matters as much as the condition of the package.

How fast it closed

The procedural history is short, and the speed is part of the story.

The magistrate judge took the plea on June 9, 2025, found the company competent to plead and the plea knowing and voluntary, and recorded that he had found that an adequate factual basis supporting the plea as to each essential offense element for the applicable charge was presented. He then recommended the outcome:

the Court RECOMMENDS that the presiding District Judge ACCEPT the guilty plea of FACIAL EXPRESSIONS and ADJUDGE it guilty of the Information.

He gave the parties an unusually short window to object — within THREE days after being served with a copy of this decision, a party may serve and file specific written objections — citing the need for prompt disposition and the Speedy Trial Act.

Nobody objected. The district judge's order, dated June 20, 2025, says so in one line:

The established three-day objection deadline has passed, and no party has objected.

And that silence had a legal consequence the order spells out, quoting the Supreme Court:

The Court is not required to “review . . . a magistrate[ judge]’s factual or legal conclusions, under a de novo or any other standard, when neither party objects to those findings.

Then the conviction:

The Court ADOPTS DE 13, ACCEPTS Defendant’s guilty plea, and ADJUDGES Defendant guilty of the Information

From the plea hearing to an adjudication of guilt: eleven days.

The money, and the part of it that was decided before sentencing

The same order dealt with forfeiture, and it is worth noting that this happened on a misdemeanor:

the Court provisionally FINDS that the property identified in the Information’s Forfeiture Allegations, see DE 8 at 7 (the money judgment of $10,911), is forfeitable

Ten thousand nine hundred and eleven dollars, described as the proceeds of the violation. The order explains the timing: under the criminal rules, and absent an objection before judgment, the preliminary forfeiture order becomes final as to the defendant at sentencing. So the forfeiture was effectively settled at the plea stage, months before any sentence was imposed.

Separately, the public announcement describes harm to customers and a figure attached to it:

Multiple customers experienced side effects linked to the botulinum injections that they received at Facial Expressions during this period.

In total, these customers incurred additional medical expenses of at least $24,369 to fix these side effects.

Two cautions on those two sentences, and we are flagging both without resolving either. The phrase linked to is not a finding of cause, and a prosecutor's public announcement is not a judicial finding of anything. The document where a court would record what it actually found about harm is the judgment — and as the next section explains, we could not read it. Also note the direction of the arithmetic: the money the company is recorded as having taken in, $10,911, is smaller than the customers' recorded additional medical costs, $24,369. We state both figures and draw no conclusion from the gap.

What this page cannot tell you: the sentence

We do not know what punishment this company received, and we want to be precise about why, because "unknown" and "unobtainable" are different claims.

The judgment exists. It is document 24 on the docket, it is held in the public court-records archive, and we downloaded it successfully on October 29, 2026. It is five pages and 163,847 bytes. It is also a photograph of a piece of paper. When we extracted its text layer, the entire five-page document yielded not one readable character — the only output was the blank page separators our own extractor inserts between pages. There is nothing in it a machine can read.

We checked two other routes before giving up on the figure:

So the honest statement is this: the company was convicted, and we cannot tell you what it was sentenced to. The statutory ceiling for this tier is quoted above. What the court actually imposed is recorded on a page nobody can read without paying for it. Anyone who tells you the outcome of this case, in either direction, is working from something other than these documents.

Three documents in this case cannot be quoted at all, including the one with the elements

This section is about our own method, and it is here because it changed what this page says.

Five documents from this docket are publicly available at no cost. Before reading any of them, we classified each one's text layer from its raw bytes, which is the only reliable way to tell a document that was typed from a document that was photographed and then machine-read. The result:

For the two middle ones, the machine-read text is readable enough to tempt you and wrong in exactly the places that matter. The strings below are not quotations of those documents — they are specimens of what the machine produced when it tried to read them, which is a different thing and is why they are set in a different typeface. In the recovered text of the charging document, the statute 331 comes out as 33l(, with a lowercase letter L standing in for the digit 1; the subsection 352(f)(1) comes out as 352(f)(l), same substitution; the word property comes out as prope1iy. In the plea agreement, misdemeanor comes out as misderneanor, Information becomes Infbnnation, and a statutory citation collapses into rs l5l.

That last one matters more than the comic ones. The plea agreement is the document that contains the government's own numbered list of the elements of this offense — the single most useful paragraph in the whole file, and the reason we chose this case. A machine's transcription of it is not a quotation of it. A person can guess what the mangled citation was meant to be, and the guess is probably right, but a guess printed inside quotation marks is a different kind of statement than a quotation, and we will not make it.

So the elements as described at the top of this page are drawn from the statute itself, which we fetched from the United States Code and quoted verbatim, and from the magistrate judge's native-text recommendation, which confirms that the court found a factual basis as to each essential offense element for the applicable charge was presented. We have not put the government's own wording of the elements on this page, because we cannot read it. That is a smaller page than the one we set out to write, and it is the correct one.

Our general method for this, including how to tell a scanned filing from a typed one, is on can you search a court filing.

Two defects in the record itself, reported and not tidied up

A citation error, in a judicial recommendation that a district judge adopted. The agreed formula quoted above cites [18 U.S.C. § 352(f)(1)]. The adequate-directions requirement is in Title 21, not Title 18. The surrounding sentence is unambiguously about the food and drug law, nothing turns on it, and we would not mention it except that it is a typing slip in the highest-authority document we read — and it was adopted without objection by a district judge. This is not the first citation defect we have found in an official record and it will not be the last. A citation field is a drafter's work at every institution, including the federal bench.

A form built for a human being, applied to a company. The recommendation puts the corporate defendant through the standard colloquy script, and the script's pronouns show. It records informing the defendant of his/her right to rearraignment, and it closes by noting that the district judge will, as necessary, address Defendant’s custodial status when considering this Recommendation. A company has no custodial status. The boilerplate is harmless here, but it is a small, honest piece of evidence about how rarely the corporate version of this proceeding comes up.

What does the evidence not show?

This is the section most pages like this one leave out. The documents we read have real limits and several of them cut against the reading above.

Where we stand on this

We said at the top that our interest here is direct, so here is the specific thing we take from this record, stated as plainly as we can.

The first and third elements of this offense describe what Artemis Labs does as a matter of routine: it receives goods it did not make, and it delivers them to people who pay. There is no version of this business that avoids those two elements, and there is no point pretending otherwise. Nor is the middle element something we could fix by writing better copy, because none of the three has anything to do with what a seller writes. Every other enforcement mechanism in this index — intended use read off a product page, a benefit claim, a disclaimer read as evidence — can in principle be managed by being careful with language. This one cannot. It turns entirely on how the article itself is characterized in law.

That is why this page exists, and it is also where the page stops. Whether any particular article is a prescription drug within the meaning of the provision quoted above is a legal question about a specific product, with a specific regulatory history, and it is a question for a lawyer looking at that product. It is not a question a vendor should be answering on its own website, including this one. We have set out the mechanism and the documents; we have deliberately not applied them to our own catalog in public.

The one practical observation we will make is the one in the symmetry section above, because it is general, not product-specific, and it points the opposite way from most compliance instincts: adding an official-looking status mark to a label is not a safe default. Under the provision quoted, a status mark on an article that does not have that status is itself a defined misbranding. Caution that takes the form of adding regulatory-looking marks can create the violation it was meant to avoid.

Sources

Every document below was fetched and read on October 29, 2026. Court filings came from the public court-records archive at no cost; a deliberately invalid document number on the same docket returned a 404, which is how we know a successful download means the document genuinely exists and not the server answering yes to everything. Each PDF's text layer was classified from its raw bytes before anything was quoted from it, and the three documents graded as scans are quoted nowhere on this page.

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.